BioTech Primer, Inc. – Trademark Portfolio

Entity Type: 03

BioTech Primer, Inc. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 16 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include BIOTECH PRIMER. The owner is based in Baltimore, MD.

8600 LaSalle Road

Ste. 605

Baltimore, MD 21286

18 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BioTech Primer, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

41
Education & Entertainment (16 filings)

Education; providing of training; entertainment; sporting and cultural activities

16
Paper Goods (3 filings)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

Frequently Asked Questions

How many trademarks does BioTech Primer, Inc. have?

BioTech Primer, Inc. has 18 U.S. trademarks filed with the USPTO. Of these, 2 registered, 10 abandoned, 3 cancelled.

What trademark classes does BioTech Primer, Inc. file in?

BioTech Primer, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 16 (Paper Goods). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.

What are BioTech Primer, Inc.'s most well-known trademarks?

BioTech Primer, Inc.'s registered trademark portfolio includes well-known marks such as BIOTECH PRIMER. These are among 2 currently registered trademarks in the portfolio.

What is BioTech Primer, Inc.'s trademark registration success rate?

BioTech Primer, Inc. has a 13% trademark registration rate, with 2 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.